Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PPT1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPT1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPT1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PPT1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PPT1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PPT1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPT1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091657 | Prostate | BPH | nucleotide biosynthetic process | 60/3107 | 254/18723 | 2.34e-03 | 1.28e-02 | 60 |
GO:00070334 | Prostate | BPH | vacuole organization | 45/3107 | 180/18723 | 2.49e-03 | 1.34e-02 | 45 |
GO:19012937 | Prostate | BPH | nucleoside phosphate biosynthetic process | 60/3107 | 256/18723 | 2.83e-03 | 1.49e-02 | 60 |
GO:0007611 | Prostate | BPH | learning or memory | 59/3107 | 255/18723 | 4.12e-03 | 2.04e-02 | 59 |
GO:00469492 | Prostate | BPH | fatty-acyl-CoA biosynthetic process | 10/3107 | 25/18723 | 4.57e-03 | 2.19e-02 | 10 |
GO:00442723 | Prostate | BPH | sulfur compound biosynthetic process | 37/3107 | 148/18723 | 5.70e-03 | 2.65e-02 | 37 |
GO:0048548 | Prostate | BPH | regulation of pinocytosis | 6/3107 | 12/18723 | 7.73e-03 | 3.39e-02 | 6 |
GO:00435244 | Prostate | BPH | negative regulation of neuron apoptotic process | 35/3107 | 145/18723 | 1.23e-02 | 4.94e-02 | 35 |
GO:001604916 | Prostate | Tumor | cell growth | 137/3246 | 482/18723 | 7.01e-10 | 3.51e-08 | 137 |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
GO:000155815 | Prostate | Tumor | regulation of cell growth | 115/3246 | 414/18723 | 6.40e-08 | 1.88e-06 | 115 |
GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
GO:007099719 | Prostate | Tumor | neuron death | 98/3246 | 361/18723 | 1.81e-06 | 3.19e-05 | 98 |
GO:000915218 | Prostate | Tumor | purine ribonucleotide biosynthetic process | 53/3246 | 169/18723 | 5.62e-06 | 8.63e-05 | 53 |
GO:190121419 | Prostate | Tumor | regulation of neuron death | 86/3246 | 319/18723 | 1.01e-05 | 1.46e-04 | 86 |
GO:003157913 | Prostate | Tumor | membrane raft organization | 14/3246 | 25/18723 | 1.41e-05 | 1.92e-04 | 14 |
GO:004592612 | Prostate | Tumor | negative regulation of growth | 70/3246 | 249/18723 | 1.48e-05 | 2.00e-04 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPT1 | insertion | Frame_Shift_Ins | novel | c.641_642insTTCTTTTGATAAAAAGGTTTTAAAACTAGCT | p.Tyr215SerfsTer29 | p.Y215Sfs*29 | P50897 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
PPT1 | SNV | Missense_Mutation | | c.304N>T | p.Asp102Tyr | p.D102Y | P50897 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PPT1 | deletion | Frame_Shift_Del | | c.422delN | p.Gly141AspfsTer27 | p.G141Dfs*27 | P50897 | protein_coding | | | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPT1 | SNV | Missense_Mutation | novel | c.92N>T | p.Ala31Val | p.A31V | P50897 | protein_coding | tolerated(0.13) | benign(0.134) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPT1 | SNV | Missense_Mutation | novel | c.374C>A | p.Ala125Asp | p.A125D | P50897 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPT1 | SNV | Missense_Mutation | rs200813294 | c.802C>T | p.Arg268Cys | p.R268C | P50897 | protein_coding | deleterious(0.03) | probably_damaging(0.988) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
PPT1 | SNV | Missense_Mutation | | c.506C>T | p.Ala169Val | p.A169V | P50897 | protein_coding | tolerated(0.5) | benign(0) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD |
PPT1 | SNV | Missense_Mutation | | c.829N>A | p.Ala277Thr | p.A277T | P50897 | protein_coding | tolerated(0.24) | benign(0.075) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD |
PPT1 | SNV | Missense_Mutation | novel | c.243N>T | p.Glu81Asp | p.E81D | P50897 | protein_coding | deleterious(0.01) | benign(0.403) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPT1 | SNV | Missense_Mutation | | c.308C>A | p.Pro103His | p.P103H | P50897 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-BG-A0M4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |